Pharmacokinetics and disposition of silodosin (KMD-3213)

Yakugaku Zasshi

Volumn 126, Issue SPEC. ISS., 2006, Pages 237-245

  Matsubara, Yasuhito ^a   Kanazawa, Toru ^a   Kojima, Yasunari ^a   Abe, Yoshikazu ^a   Kobayashi, Kaoru ^a   Kanbe, Hiroki ^a   Harada, Hiroshi ^a   Momose, Yasunori ^a   Terakado, Sakae ^b   Adachi, Yasuhisa ^b   Midgley, Ian ^c  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

^b DAIICHI PURE CHEMICALS CO LTD   (Japan)

^c HUNTINGDON LIFE SCIENCES   (United Kingdom)

Author keywords

1A adrenoceptor antagonist; Metabolism; Pharmacokinetics; Silodosin (KMD 3213); Species differences

Indexed keywords

ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; CARBON 14; CYTOCHROME P450 3A4; DRUG METABOLITE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; OROSOMUCOID; SILODOSIN; SILODOSIN C 14; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY WATER; BRAIN; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FECES; GASTROINTESTINAL TRACT; HUMAN; HUMAN TISSUE; KIDNEY; LIVER; LIVER BLOOD FLOW; LIVER CLEARANCE; MALE; NONHUMAN; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; RADIOACTIVITY; RAT; SEX ROLE; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; CACO-2 CELLS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; GASTROINTESTINAL TRACT; HALF-LIFE; HUMANS; INDOLES; INTESTINAL ABSORPTION; MALE; PROTEIN BINDING; RATS; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 33645007471     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.126.237     Document Type: Article

References (13)

1. Anderle P., Niederer E., Rubas W., Hilgendorf C., Spahn-Langguth H., Wunderli-Allenspach H., Merkle H. P., Langguth P., J. Pharm. Sci., 87, 757-762 (1998).
2. Cavet M. E., West M., Simmons N. L., Br. J. Pharmacol., 118, 1389-1396 (1996).
3. Davies B., Morris T., Pharm. Res., 10, 1093-1095 (1993).
4. Dedrick R. L., Forrester D. D., Cannon J. N., El Dareer S. M., Mellett L. B., Biochem. Pharmacol., 22, 2405-2417 (1973).
5. Kolars J. C., Lown K. S., Schmiedlin-Ren P., Ghosh M., Fang C., Wrighton S. A., Merion R. M., Watkins P. B., Pharmacogenetics, 4, 247-259 (1994).
6. Thummel K. E., Wilkinson G. R., Annu. Rev. Pharmacol. Toxicol., 38, 389-430 (1998).
7. Wacher V. J., Wu C.-Y., Benet L. Z., Mol. Carcinog., 13, 129-134 (1995).
8. Ambudkar S. V., Dey S., Hrycyna C. A., Ramachandra M., Pastan I., Gottesman M. M., Annu. Rev. Pharmacol. Toxicol., 39, 361 -398 (1999).
9. Zhang Y., Benet L. Z., Clin. Pharmacokinet., 40, 159-168 (2001).
10. Hall S. D., Thummel K. E., Watkins P. B., Lown K. S., Benet L. Z., Paine M. F., Mayo R. R., Turgeon D. K., Bailey D. G., Fontana R. J., Wrighton S. A., Drug Metab. Dispos., 27, 161-166 (1999).
11. Tukey R. H., Strassburg C. P., Annu. Rev. Pharmacol. Toxicol., 40, 581-616 (2000).
12. Kera Y., Ohbora Y., Komura S., Biochem. Pharmacol., 37, 3633-3636 (1988).
13. Goon D., Cheng X., Ruth J. A., Petersen D. R., Ross D., Toxicol. Appl. Pharmacol., 114, 147-155 (1992).